Bristol Myers Squibb

Bristol Myers Squibb

Bristol Myers Squibb

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

Bristol Myers Squibb

Address

Roma, Lazio, Italy

Contact

n.a.

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with Bristol Myers Squibb

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

Bristol Myers Squibb last news

26/01/2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)

BALA CYNWYD, Pa., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Karuna Therapeutics, Inc. (Nasdaq – KRTX) Under the terms of the Merger Agreement, Karuna Therapeutics will be acquired by Bristol Myers Squibb (NYSE:BMY) in an all-cash transaction valued at approximately $14 billion. Karuna Therapeutics stockholders will receive $330.00 per share in cash upon completion of the proposed transaction. The investigation concerns whether the Karuna Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Bristol Myers Squibb is paying fair value to shareholders of the Company. Additional information can be found at https://www.brodskysmith.com/cases/karuna-therapeutics-inc-nasdaq-krtx/. Carrols Restaurant Group, Inc. (Nasdaq - TAST) Under the ...Full story available on Benzinga.com

26/01/2024

BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma

Bristol Myers Squibb announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended ... read more

26/01/2024

Sanders says pharma CEOs facing possible subpoenas will testify about drug prices

The CEOs of Johnson & Johnson and Merck have agreed to testify at a Senate hearing in February about prescription drug prices and will not face a subpoena, Sen. Bernie Sanders (I-Vt.) said Friday. The Senate Health, Education, Labor and Pensions (HELP) Committee hearing will take place on Feb. 8. Johnson & Johnson CEO Joaquin Duato,...